XJPX3750
Market cap50mUSD
Jan 14, Last price
886.00JPY
1D
0.11%
1Q
4.24%
Jan 2017
251.59%
Name
Cytori Cell Research Institute Inc
Chart & Performance
P/E
57.26
P/S
5.07
EPS
15.47
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
-18.66%
Revenues
1.56b
-27.24%
Net income
138m
P
CFO
-1.15b
L+2,815.71%
Dividend
Mar 27, 201920 JPY/sh
Profile
Cytori Cell Research Institute, Inc., engages in the research, development, production, and sale of cell therapy related medical devices in Japan. The company sells cell therapy kits, as well as engages in the research and development of cell therapy technology, etc. Its products pipeline includes ECCI-50 for the treatment of male stress urinary incontinence and liver cirrhosis; and Cyt-006 to prevent postoperative adhesion for primary rectal cancer. The company is also conducting clinical trials/research on cell therapy for a range of diseases and applications, including anterior cruciate ligament repair, bone repair, burn scars, chronic wound healing, critical limb ischemia, anal and Crohn's disease fistulas, erectile dysfunction, etc. It also invests in, owns, develops, leases, and manages real estate projects and hotels; and provides real estate brokerage services. The company was formerly known as FRACTALE Corporation. Cytori Cell Research Institute, Inc. was incorporated in 2004 and is headquartered in Tokyo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | |
| Income | |||||
Revenues | 1,560,388 -27.24% | 2,144,712 60.58% | 1,335,578 -3.80% | ||
Cost of revenue | 619,353 | 2,803,959 | 1,593,345 | ||
Unusual Expense (Income) | |||||
NOPBT | 941,035 | (659,247) | (257,767) | ||
NOPBT Margin | 60.31% | ||||
Operating Taxes | (1,150,152) | (106,345) | 11,757 | ||
Tax Rate | |||||
NOPAT | 2,091,187 | (552,902) | (269,524) | ||
Net income | 138,155 -113.03% | (1,059,941) 1,265.32% | (77,633) -90.67% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 258,655 | ||||
BB yield | -2.53% | ||||
| Debt | |||||
Debt current | 124,685 | 901,237 | 717,667 | ||
Long-term debt | 2,347,079 | 7,605,855 | 8,550,792 | ||
Deferred revenue | |||||
Other long-term liabilities | 12,375 | 1,219,098 | 1,226,869 | ||
Net debt | 1,284,537 | 7,254,042 | 8,222,901 | ||
| Cash flow | |||||
Cash from operating activities | (1,152,230) | (39,518) | (187,784) | ||
CAPEX | (16,256) | (158,520) | (180,045) | ||
Cash from investing activities | 8,689,978 | (283,065) | (216,193) | ||
Cash from financing activities | (7,172,572) | 294,227 | 35,797 | ||
FCF | 9,600,834 | 1,660,749 | (1,757,451) | ||
| Balance | |||||
Cash | 1,038,227 | 1,123,050 | 851,558 | ||
Long term investments | 149,000 | 130,000 | 194,000 | ||
Excess cash | 1,109,208 | 1,145,814 | 978,779 | ||
Stockholders' equity | (142,197) | (282,914) | 777,598 | ||
Invested Capital | 5,421,924 | 12,665,785 | 13,434,182 | ||
ROIC | 23.12% | ||||
ROCE | 17.41% | ||||
| EV | |||||
Common stock shares outstanding | 8,959 | 8,929 | 8,830 | ||
Price | 970.00 -14.39% | 1,133.00 -2.24% | 1,159.00 -19.57% | ||
Market cap | 8,690,093 -14.10% | 10,116,045 -1.15% | 10,233,793 -13.23% | ||
EV | 9,979,421 | 17,374,094 | 18,460,492 | ||
EBITDA | 1,195,345 | (327,756) | 63,278 | ||
EV/EBITDA | 8.35 | 291.74 | |||
Interest | 153,811 | 129,241 | 93,194 | ||
Interest/NOPBT | 16.34% | ||||